How long does it really take to get an FDA market decision? How much value is created when you reach a regulatory or clinical milestone? Kwame Ulmer has spent the last 18 years working with medical device companies helping them answer these questions. The event will include an overview of key regulatory considerations for leaders at medical device companies who are looking to navigate the FDA.
Ayse McCracken, CPA MBA is the President of eNNOVATE Health Ventures LLC in Houston, Texas. After serving three decades as a senior executive in venture backed companies and some of the country’s most prominent healthcare systems, she now focuses her knowledge and energy on businesses seeking to revolutionize the delivery of healthcare. Ayse serves as an advisor at TMCx, a board member of nationally recognized nonprofit BakerRipley, a member of NACD and is the founding board member of Ignite Healthcare Network.
Abilitech Medical, Inc. is developing a suite of assistive devices, which will restore functional use to arms and hands and allow people to regain the ability to perform activities of daily living. Abilitech’s product portfolio will include an arm assist device (Abilitech Assist), a powered handgrip device (Abilitech Powered Handgrip), and a fully robotic, voice-controlled arm and hand assist device (Abilitech APEX Robotic Assist). These and other products will address the needs of a vast array of people with varying degrees of upper extremity dysfunction.
Ejenta is an AI platform that allows health providers to remotely deliver care at scale. Our technology is exclusively licensed from NASA, where our founder developed AI to remotely support astronauts in some of the toughest conditions in space. We're now applying our experience to improve the care of millions of patients on Earth.
Emergency Medical Innovation, LLC was founded by Dr. Elizabeth Clayborne, an emergency physician who developed the medical device Bleed Freeze for treatment of nosebleeds. Bleed Freeze provides a safe, effective and low-cost solution for nosebleed rescue that will be the go-to “Band-Aid®” of nosebleeds for children, adults and medical providers.
Our passion for helping patients focuses us on what remains in the patient, not what has already been removed. We believe that all breast cancer patients deserve the opportunity to move beyond their breast cancer surgery knowing that all the cancer has been removed, the first time. In everything we do, we are thinking about how we can inch closer to a world free from repeat operations... We are going BEYOND BREAST CANCER.
During the IGNITE Madness Finals, Accenture will be hosting a panel discussion with Stefani Benefield, Senior Vice President of Virtual Care at Best Buy Health and Megan Zweig, Chief Operating Officer of Rock Health. We hope you'll join them as they discuss how big & small companies alike are getting in the healthcare game, how to ensure healthcare is human-centric, and what holes in the system COVID-19 has brought to light.
Abilitech Medical, Inc. is a medical device company based in Minneapolis, Minnesota. The company's vision is to build a suite of products that will revolutionize the way in which clinicians and patients view and treat neuromuscular conditions.
In 2016, Abilitech Medical, Inc. was founded by a group of deeply committed and knowledgeable individuals experienced with upper-limb impairments. Since inception, the team has worked to create and build solutions that restore function and independence to those affected by neuromuscular conditions.
The Abilitech™ Assist is the first in-home device on the market that will provide functional assistance and support to both the elbow and shoulder. This device has the potential to improve the lives of hundreds of thousands of patients living with Muscular Dystrophy and Multiple Sclerosis.
Chosen Diagnostics aims to improve health care delivery for patients by personalizing their treatment. Initially the company is focused on developing two novel biomarker diagnostic kits: one for a common gastrointestinal disease in premature infants and a second to assess how likely a patient is to respond to certain drug treatments.
Ejenta’s platform is based on AI technology, exclusively licensed from NASA, where intelligent agents currently run 24/7 in NASA's Mission Control for the International Space Station.
Intelligent agents use data from sensors and IoT devices to learn about their users, detect abnormalities and predict health deterioration in advance.
Intelligent agents interact with their users to encourage healthy behavior, and they act autonomously to communicate, present actionable data and keep care teams connected.